Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 10/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462205 | 0.79 | GLS (0.48) | HRH4HRH3HSP90AB1 | |
| SCHEMBL453620 | 0.78 | HDAC3 (0.38) | EP300 | |
| SCHEMBL462628 | 0.77 | HRH4 (0.44) | NCF1HRH4HRH3HSP90AB1MPO | |
| SCHEMBL27088132 | 0.68 | MAOA (0.39) | NCF1HRH4HRH3HSP90AB1 | |
| SCHEMBL455751 | 0.68 | GPR84 (0.49) | HRH4HRH3 | |
| SCHEMBL462931 | 0.67 | CYP19A1 (0.43) | NCF1HSP90AB1 | |
| SCHEMBL460447 | 0.66 | TEK (0.55) | — | |
| SCHEMBL317261 | 0.65 | — | — | |
| SCHEMBL28174204 | 0.64 | NOTUM (0.43) | HRH4HRH3HSP90AB1 | |
| SCHEMBL12594675 | 0.63 | HRH4 (0.54) | HRH4HRH3EP300MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2613630-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Cempra Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2012034058-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | NCF1 2526/4885HRH4 3514/4885HRH3 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.